Multicenter phase 1-2 study of first-line daraxonrasib plus chemotherapy for metastatic pancreatic ductal adenocarcinoma

Oncogenic RAS mutations occur in more than 90% of metastatic pancreatic ductal adenocarcinomas (mPDAC). Daraxonrasib is an oral, RAS(ON) multiselective inhibitor targeting GTP-bound mutant and wild-type RAS. It is approved for the treatment of adult patients with mPDAC who have received at least on prior systemic therapy or are not candidates for multiagent systemic therapy. A high unmet need remains in first-line treatment of mPDAC, where current chemotherapy regimens provide limited clinical benefit. The multicenter phase1-2 RMC-GI-102 study evaluated daraxonrasib plus gemcitabine and nab-paclitaxel chemotherapy (GnP) as first-line treatment for mPDAC and found a manageable safety profile and encouraging antitumor efficacy, irrespective of RAS mutation status (including wild-type RAS tumors). Updated safety and more mature efficacy results from the study have been reported yesterday at the EORTC-NCI-AACR Symposium in Barcelona (Spain). As of September 28, 2026 (median follow-up 18.3 months; range 13.1-23.7), 61 mPDAC patients had received daraxonrasib plus GnP. Safety profile was consistent with prior reports; no new safety signals were identified with longer follow-up. The objective response rate was 60.7% (95% CI 47.3-72.9), including complete response in 8.2%, and the disease control rate was 90.2% (79.8-96.3). The median progression-free survival was 12.8 months (95% CI 10.8-18.4). The authors conclude that first-line daraxonrasib plus GnP demonstrated a clinically meaningful activity and a consistent safety profile among mPDAC patients. The global phase 3 RASolute 303 study of first-line daraxonrasib plus GnP for mPDAC is ongoing.